VolitionRx posts $1 million Q1 revenue, up 300% year over year

VolitionRX Ltd

VolitionRX Ltd

VNRX

0.00
  • VolitionRx posted Q1 2026 revenue of USD 1 million, up 300% year over year.
  • Submitted a feline lymphoma manuscript for the Nu.Q Vet cancer test; a USD 5 million milestone payment is expected after publication.
  • Reported active licensing talks with more than a dozen global diagnostics or liquid biopsy groups, including technical evaluations.
  • Capture-Seq validation cohort detected over 95% of Stage I–II cancers with 95% specificity; estimated annualized cancer-detection TAM of USD 23 billion.
  • Nu.Q NETs assay included in France’s DETECSEPS program backed by about USD 7.3 million; sepsis or chronic TAM estimated at USD 3.8 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.